Abstract 1958 Construction of a synthetic probiotic bacteria to in-situ delivery of anti-SARS-CoV2-nanobodies

SARS-CoV-2 viral infection can be inhibited by blocking the interaction between viral spike protein and the human receptor angiotensin-converting enzyme 2 (hACE2). The development of specific spike inhibitors using nanobodies, the antigen-binding region of llama's antibodies, arose as a promising therapeutic method against SARS-CoV-2. However, one limitation of nanobodies is that they cannot be used directly in the human body due to their susceptibility to degradation. Bacteria-based delivery systems provide site-specific targeted action that can circumvent nanobody degradation.